×
It looks like you're using an obsolete version of internet explorer. Internet explorer is no longer supported by Microsoft since the end of 2015. We invite you to use a newer browser such as Firefox, Google Chrome or Microsoft Edge.
My Player placeholder

Become an Oncostream member and receive full access to its content!

You must be an Oncostream member to access videos without any restrictions. Register for free in one minute and access all services provided by Oncostream.You will also be able to log into Oncostream from your Facebook or twitter account by clicking on login on the top-right corner of Oncostream website.

Registration Login


Worldwide schedules comment Share

Au programme de cette soirée

18:30 Introduction
 
18:35 Prise en charge chirurgicale de la patiente âgée
Dr Naoual Bakrin
 
19:00 Patiente âgée : quelle stratégie thérapeutique adopter ?
Dr Leïla Bengrine
 
19:25 Optimisation et suivi d’un traitement par iPARP chez la patiente âgée
Pr Antonin Schmitt
 
19:50 Réponses aux questions - Débat/Discussion - Take Home message
 

 

Episode 1   Episode 3

 

Shooting date : 2023-10-10
Last update : 2023-10-12
1 comment
Join the Discussion
  • Wessim E. Chez une patiente multitarée avec a l echographie et l'IRM on a 2 images ovariennes supectes + carcinose péritonéale mais avec une biopsie scannoguidée négative et impossibilité de réaliser la coelio, quelles sont les alternatives therapeutiques?

      Please, select your files, click upload button, write your comment and click the send button. (allowed formats : images jpeg, gif, png, and PDF)
      Your browser doesn't have Flash, Silverlight or HTML5 support.


    Suggestions

    Wednesday, November 10th 2021 from 06pm to 07:30pm (GMT+1)
    Honolulu : Wednesday, November 10th 2021 from 07am to 08:30am (GMT+1)
    San Francisco : Wednesday, November 10th 2021 from 09am to 10:30am (GMT+1)
    New York : Wednesday, November 10th 2021 from 12pm to 01:30pm (GMT+1)
    Buenos Aires : Wednesday, November 10th 2021 from 02pm to 03:30pm (GMT+1)
    London / Dublin : Wednesday, November 10th 2021 from 05pm to 06:30pm (GMT+1)
    Paris / Berlin : Wednesday, November 10th 2021 from 06pm to 07:30pm (GMT+1)
    Istanbul : Wednesday, November 10th 2021 from 07pm to 08:30pm (GMT+1)
    Moscou / Dubaï : Wednesday, November 10th 2021 from 09pm to 10:30pm (GMT+1)
    Bangkok : Thursday, November 11th 2021 from 12am to 01:30am (GMT+1)
    Shanghai : Thursday, November 11th 2021 from 01am to 02:30am (GMT+1)
    Tokyo : Thursday, November 11th 2021 from 02am to 03:30am (GMT+1)
    Sydney : Thursday, November 11th 2021 from 03am to 04:30am (GMT+1)
    Wellington : Thursday, November 11th 2021 from 05am to 06:30am (GMT+1)

    La prise en compte de la qualité de vie, des choix des patientes en cancérologie gynécologique

    Comment passer des recommandations de Saint-Paul-de-Vence à la pratique quotidienne ?

    Share
    Tuesday, November 30th 2021 from 06pm to 08pm (GMT+1)
    Honolulu : Tuesday, November 30th 2021 from 07am to 09am (GMT+1)
    San Francisco : Tuesday, November 30th 2021 from 09am to 11am (GMT+1)
    New York : Tuesday, November 30th 2021 from 12pm to 02pm (GMT+1)
    Buenos Aires : Tuesday, November 30th 2021 from 02pm to 04pm (GMT+1)
    London / Dublin : Tuesday, November 30th 2021 from 05pm to 07pm (GMT+1)
    Paris / Berlin : Tuesday, November 30th 2021 from 06pm to 08pm (GMT+1)
    Istanbul : Tuesday, November 30th 2021 from 07pm to 09pm (GMT+1)
    Moscou / Dubaï : Tuesday, November 30th 2021 from 09pm to 11pm (GMT+1)
    Bangkok : Wednesday, December 1st 2021 from 12am to 02am (GMT+1)
    Shanghai : Wednesday, December 1st 2021 from 01am to 03am (GMT+1)
    Tokyo : Wednesday, December 1st 2021 from 02am to 04am (GMT+1)
    Sydney : Wednesday, December 1st 2021 from 03am to 05am (GMT+1)
    Wellington : Wednesday, December 1st 2021 from 05am to 07am (GMT+1)

    Cancer de l’ovaire : observance long terme sous inhibiteurs de PARP

    Episode 2

    Share
    Tuesday, April 12th 2022 from 06pm to 07:30pm (GMT+2)
    Honolulu : Tuesday, April 12th 2022 from 07am to 08:30am (GMT+2)
    San Francisco : Tuesday, April 12th 2022 from 10am to 11:30am (GMT+2)
    New York : Tuesday, April 12th 2022 from 01pm to 02:30pm (GMT+2)
    Buenos Aires : Tuesday, April 12th 2022 from 02pm to 03:30pm (GMT+2)
    Reykjavik : Tuesday, April 12th 2022 from 05pm to 06:30pm (GMT+2)
    London / Dublin : Tuesday, April 12th 2022 from 06pm to 07:30pm (GMT+2)
    Paris / Berlin : Tuesday, April 12th 2022 from 07pm to 08:30pm (GMT+2)
    Istanbul : Tuesday, April 12th 2022 from 08pm to 09:30pm (GMT+2)
    Moscou / Dubaï : Tuesday, April 12th 2022 from 09pm to 10:30pm (GMT+2)
    Bangkok : Wednesday, April 13th 2022 from 12am to 01:30am (GMT+2)
    Shanghai : Wednesday, April 13th 2022 from 01am to 02:30am (GMT+2)
    Tokyo : Wednesday, April 13th 2022 from 02am to 03:30am (GMT+2)
    Sydney : Wednesday, April 13th 2022 from 04am to 05:30am (GMT+2)
    Wellington : Wednesday, April 13th 2022 from 06am to 07:30am (GMT+2)

    Cancers séreux de bas grade

    Share
    Tuesday, November 21st 2023 from 06pm to 07:30pm (GMT+1)
    Honolulu : Tuesday, November 21st 2023 from 07am to 08:30am (GMT+1)
    San Francisco : Tuesday, November 21st 2023 from 09am to 10:30am (GMT+1)
    New York : Tuesday, November 21st 2023 from 12pm to 01:30pm (GMT+1)
    Buenos Aires : Tuesday, November 21st 2023 from 02pm to 03:30pm (GMT+1)
    London / Dublin : Tuesday, November 21st 2023 from 05pm to 06:30pm (GMT+1)
    Paris / Berlin : Tuesday, November 21st 2023 from 06pm to 07:30pm (GMT+1)
    Istanbul : Tuesday, November 21st 2023 from 07pm to 08:30pm (GMT+1)
    Moscou / Dubaï : Tuesday, November 21st 2023 from 09pm to 10:30pm (GMT+1)
    Bangkok : Wednesday, November 22nd 2023 from 12am to 01:30am (GMT+1)
    Shanghai : Wednesday, November 22nd 2023 from 01am to 02:30am (GMT+1)
    Tokyo : Wednesday, November 22nd 2023 from 02am to 03:30am (GMT+1)
    Sydney : Wednesday, November 22nd 2023 from 03am to 04:30am (GMT+1)
    Wellington : Wednesday, November 22nd 2023 from 05am to 06:30am (GMT+1)

    Cancer de l'ovaire : comment évaluer aujourd'hui la recombinaison homologue ?

    Share
    Scroll Up